Arcellx, Inc.
ACLX
Rangering i aksjer
#2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aksjekurs
$115.07
Sist synkronisert: 2026-05-15
Markedsverdi
$6.73B
Endring (1 dag)
0.00%
Endring (1 år)
32.61%
Land
US
Handel Arcellx, Inc. (ACLX)
Kategori
Healthcare
P/B-forhold for Arcellx, Inc. (ACLX)
P/B-forhold per October 2026 TTM: 16.10
Ifølge Arcellx, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 16.10. Ved slutten av 2023 hadde selskapet et P/B-forhold på 5.50.
P/B-historikk for Arcellx, Inc. fra 2018 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 16.10 | 78.33% |
| 2024 | 9.03 | 64.37% |
| 2023 | 5.50 | -17.57% |
| 2022 | 6.67 | 32.34% |
| 2021 | 5.04 | -30.41% |
| 2020 | 7.24 | -140.56% |
| 2019 | -17.85 | -9,055.54% |
| 2018 | 0.20 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -61.18% |
US
|
|
| 13.2547 | -17.69% |
US
|
|
| 4.208 | -73.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -61.61% |
NL
|
